Patterns of Inhaled Asthma Medication Use: a 3-year Longitudinal Analysis of Prescription Claims Data from British Columbia, Canada
Overview
Affiliations
Study Objectives: To assess trends in asthma management and to identify factors associated with increasing short-acting (SA) beta-agonist utilization in British Columbia using administrative prescription data.
Design: A retrospective cohort analysis.
Setting: All patients between 13 and 50 years of age who had received at least one prescription for a SA beta-agonist covered by BC Pharmacare between January 1, 1996, and December 31, 1998.
Methods: Cross-sectional analysis of all patients, and longitudinal analyses only of patients who had received at least one SA beta-agonist prescription in each of the 3 years. Trends in asthma medication use over time were evaluated using repeated-measures Mantel-Haenszel tests. Multiple logistic regression was used to identify factors associated with increasing SA beta-agonist use.
Results: A total of 78,758 patients were included in the cohort. No decrease in the annual prevalence of receiving more than four canisters per year of a SA beta-agonist was identified between 1996 and 1998. A total of 12,844 patients filled at least one SA beta-agonist prescription each year. Time-trend analysis showed an overall increasing probability of not receiving an inhaled corticosteroid (ICS) agent in this population (p = 0.002). In patients exhibiting low SA beta-agonist use, > 18 years of age (adjusted odds ratio [OR], 1.5), male gender (adjusted OR, 1.7), and in receipt of social assistance (adjusted OR, 2.3) were associated with receiving increasing amounts of SA beta-agonist agents over the 3 years. In patients with a high degree of use of SA beta-agonists, only the receipt of social assistance (adjusted OR, 1.3) was significantly associated with increasing use.
Conclusions: Despite the development and dissemination of asthma management guidelines, there was no trend toward decreasing SA beta-agonist use. An unexpected trend toward decreasing ICS utilization was identified. Receiving social assistance was a risk factor for increasing SA beta-agonist use, independent of baseline utilization.
Sorribas Morlan M, Galmes Garau M, Esteva Canto M, Leiva Rus A, Roman-Rodriguez M Aten Primaria. 2020; 52(9):600-607.
PMID: 32571597 PMC: 7713391. DOI: 10.1016/j.aprim.2020.03.004.
Tavakoli H, FitzGerald J, Lynd L, Sadatsafavi M BMC Pulm Med. 2018; 18(1):33.
PMID: 29433489 PMC: 5809893. DOI: 10.1186/s12890-018-0598-4.
ASSESSMENT OF SOCIOECONOMIC STATUS AND CONTROL OF ASTHMA IN ADULTS.
Azeez I, Ladipo M, Ige O Ann Ib Postgrad Med. 2017; 14(2):85-91.
PMID: 28337093 PMC: 5354626.
Quality of asthma care under different primary care models in Canada: a population-based study.
To T, Guan J, Zhu J, Lougheed M, Kaplan A, Tamari I BMC Fam Pract. 2015; 16:19.
PMID: 25886504 PMC: 4336688. DOI: 10.1186/s12875-015-0232-y.
Direct health care costs associated with asthma in British Columbia.
Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan W, Sullivan S Can Respir J. 2010; 17(2):74-80.
PMID: 20422063 PMC: 2866215. DOI: 10.1155/2010/361071.